{
  "title": "Paper_605",
  "abstract": "pmc Front Chem Front Chem 2396 frontchem Front. Chem. Frontiers in Chemistry 2296-2646 Frontiers Media SA PMC12476949 PMC12476949.1 12476949 12476949 41031123 10.3389/fchem.2025.1645334 1645334 1 Mini Review Quinolines: the role of substitution site in antileishmanial activity Elso and García Liñares 10.3389/fchem.2025.1645334 Elso Orlando G. *  † Formal analysis Writing – original draft Visualization Conceptualization Investigation Writing – review & editing García Liñares Guadalupe *  † Investigation Formal analysis Writing – original draft Writing – review & editing Funding acquisition Visualization Project administration Conceptualization  Laboratorio de Biocatálisis. Departamento de Química Orgánica y UMYMFOR, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria Buenos Aires Argentina * linares@qo.fcen.uba.ar oelso@qo.fcen.uba.ar † ORCID: Orlando G. Elso, orcid.org/0000-0002-1970-9904 orcid.org/0000-0002-2946-4795 15 9 2025 2025 13 481072 1645334 11 6 2025 27 8 2025 15 09 2025 30 09 2025 01 10 2025 Copyright © 2025 Elso and García Liñares. 2025 Elso and García Liñares https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) Leishmaniasis is one of the most widespread parasitic diseases in the world, primarily affecting the poorest and most vulnerable populations. The development of new therapeutic agents that are more efficient, safe, and selective remains a challenge. The quinoline framework emerges as a privileged scaffold for this purpose. This mini-review comprehensively analyses advancements from the last two decades on 2-, 3-, 6-, and 8-substituted quinolines, as well as polysubstituted analogues, as potential antileishmanial agents, focusing on how the position and nature of substituents influence their activity. Although the assays were conducted in different Leishmania quinolines antiprotozoal activity substitution antileishmanial agents leishmaniasis Secretaria de Ciencia y Tecnica, Universidad de Buenos Aires 10.13039/501100007351 Consejo Nacional de Investigaciones Científicas y Técnicas 10.13039/501100002923 The author(s) declare that financial support was received for the research and/or publication of this article. UBA (UBACYT 20020190100242BA) and CONICET (PIP 11220210100072). pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement no pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes section-in-acceptance Medicinal and Pharmaceutical Chemistry 1 Introduction Leishmaniasis is the second most widespread protozoan disease globally. It is a parasitic infection caused by protozoa of the Leishmania García Liñares et al., 2006 Kumari et al., 2021 World Health Organization, 2025 The main drugs used to treat leishmaniasis are pentavalent antimonials, amphotericin B, and pentamidine ( Pradhan et al., 2022 Silva Santos et al., 2020 Brindha et al., 2021 In line with this, N Aatif et al., 2022 Heravi and Zadsirjan, 2020 Marshall et al., 2024 Yaluff et al., 2025 Ajani et al., 2022 Avanzo et al., 2025 Particularly, quinoline-based compounds have arisen as a privileged scaffold for the development of more selective and potent antileishmanial agents. Based on currently used antimalarial drugs, the most significant development to date concerns 4-substituted quinolines ( Delgado et al., 2025 Romero and Delgado, 2025 Avanzo et al., 2025 Ravindar et al., 2023 Vandekerckhove et al., 2013 Teng et al., 2018 Afzal et al., 2015 Nefertiti et al., 2018 Rajesh, 2018 2 Substituted quinolines 2.1 2-Substitution Given the antileishmanial activity of natural 2-substituted quinoline alkaloids ( Fournet et al., 1993 1996 Fakhfakh et al., 2003 Franck et al., 2004 in vitro L. amazonensis L. infantum 50 in vitro in vivo L. amazonensis L. infantum L. donovani in vitro in vivo in vitro L. infantum L. donovani Nakayama et al., 2005 in vitro L. donovani in vivo Nakayama et al., 2007 The synthesis of a group of quinoline-2-carbohydrazides yielded compounds 5a and 5b as the most active against Leishmania (Viannia) panamensis Coa et al., 2015 Alodeani et al., 2015 GDP-mannose pyrophosphorylase, which is involved in the biosynthetic pathway of glycoconjugates, has been recognized as an interesting target for the development of chemotherapeutic agents. Among several selected inhibitors, compound 6 emerged as the most promising antileishmanial agent, with an IC 50 L. donovani Mao et al., 2017 The primary strength of C-2 substitution lies in the accessibility for introducing different groups, which allows for an easy structural optimization. Despite this, a disconnection between in vitro in vivo 2.2 3-Substitution Based on previous studies describing the antileishmanial activity of 3-arylquinolines, this structure was selected as the lead to perform different substitution modifications at various positions ( Katsuno et al., 2015 Ortiz et al., 2017 L. amazonensis Fakhfakh et al., 2003 L. mexicana 50 Chanquia et al., 2019 Synthesis of hybrid molecules constitutes an attractive strategy for obtaining pharmaceutical compounds, which involves the covalent combination of two biologically active pharmacophores ( Viegas-Junior et al., 2007 Ammar et al., 2021 Hu et al., 2017 Singh et al., 2022 L. donovani 50 50 50 Bhat et al., 2021 Simple substitutions at C-3 have generally failed to produce potent compounds but the design of hybrid molecules with complex pharmacophores could yield more selective compounds. Additionally, a general lack of in vivo 2.3 6-Substitution Substitution on the benzene ring also presents alternatives for the development of new drugs. Based on the concept of molecular hybridization, two series of 6-substituted quinolines linked to either oxadiazole-thiosemicarbazides or 1,3,4-thiadiazoles were synthesized. The in vitro L. major 50 50 Taha et al., 2017 50 Almandil et al., 2019 The primary strength of the 6-substitution is the extremely high in vitro 2.4 8-Substitution The 8-position of the quinoline ring is historically significant due to the antimalarial drug primaquine. A group of N Da Silva et al., 2007 L. amazonensis L. chagasi L. amazonensis 50 L. amazonensis L. (V) panamensis Coa et al., 2020 Silva et al., 2018 Chalcone, furochalcone, and chromone–quinoline hybrids via an alkyl linker have also been tested against L. (Viannia) panamensis Coa et al., 2017 García et al., 2018 L (V) panamensis 50 The low cytotoxicity constitutes the main strength of the 8-substitution pattern. Additionally, some compounds showed very potent activity against the clinically relevant amastigote form. 2.5 Polisubstitution Considering the groups and substitution positions that have led to compounds with higher activity, new quinolines have been developed, combining different substituents at various positions. For example, a series of 2-styrylquinolines with additional groups at the C-7 position was synthesized and evaluated in vitro L. donovani Loiseau et al., 2011 50 2 In vitro in vivo L donovani Gopinath et al., 2013 50 in vivo L. donovani Considering the hybridization approach and the known antiparasitic activity of metronidazoles, a series of quinoline-metronidazole hybrids was synthesized and evaluated against L. donovani Upadhyay et al., 2019 L. donovani in vitro in vivo in vitro 50 in vivo Consequently, a series of 3-aryl and 3-heteroaryl- N 7 N 7 L. mexicana 50 Hammill et al., 2021 in vivo Considering the antileishmanial activity of quinoline and 1,2,3-triazole scaffolds, a series of triazolyl 2-methyl-4-phenylquinoline-3-carboxylate derivatives was synthesized via click chemistry-based molecular hybridization approach and evaluated against L. donovani Upadhyay et al., 2018 L. donovani Clioquinol (20), a dihalogenated 8-hydroxyquinoline, showed promising in vitro L. infantum L. amazonensis 50 50 3 in vivo Tavares et al., 2018 L. mexicana 50 Isaac-Márquez et al., 2010 The obvious strength of polysubstitution is the possibility of designing more active and selective molecules, optimizing pharmacokinetic and pharmacodynamic properties, although at the cost of increased synthetic complexity. The structures of the most representative compounds are shown in the Figure 1 Table 1 50 vitro in vivo FIGURE 1 Structures of the more representative substituted quinolines with antileishmanial activity. A collection of chemical structures labeled sequentially from 1 to 21, illustrating various organic compounds with different side groups, rings, and substitutions. Each structure includes distinct identifiers like halogens, nitrogen groups, or other functional groups, with variations and annotations indicated by labels such as R, R1, R2, and so on, representing different substituents in the molecules. TABLE 1 Antileishmanial data for selected substituted quinolines. Compound  In vitro  In vivo Cytotoxicity Selectivity index (SI) Reference  2-substitution 1  L. amazonensis 50 L. infantum 50 No activity CC 50 2.0  Fakhfakh et al. (2003) Nakayama et al. (2005) 2  L. amazonensis 50 L. infantum 50 No activity CC 50 8.5  Fakhfakh et al. (2003) Nakayama et al. (2005) 3  L. amazonensis 50 L. infantum 50 No activity CC 50 4.3  Fakhfakh et al. (2003) Nakayama et al. (2005) 4  L. donovani 50 83% reduction of parasite burden in liver  Nakayama et al. (2007) 5a  L. (V) panamensis 50 ND CC 50 4.5  Coa et al. (2015) 5b  L. (V) panamensis 50 ND CC 50 4.71  Coa et al. (2015) 6  L. donovani 50 ND CC 50 >94.3 (in BMDM)  Mao et al. (2017)  3-substitution 7a  L. mexicana 50 ND CC 50 >2.4  Chanquia et al. (2019) 7a  L. mexicana 50 ND CC 50 » 2.4  Chanquia et al. (2019)  6-substitution 9a  L. major 50 ND ND -  Taha et al. (2017) 9b  L. major 50 ND ND -  Taha et al. (2017) 10a  L. major 50 ND ND -  Almandil et al. (2019) 10b  L. major 50 ND ND -  Almandil et al. (2019) 10c  L. major 50 ND ND -  Almandil et al. (2019) 10d  L. major 50 ND ND -  Almandil et al. (2019)  8-substitution 11a  L. amazonensis 50 L. amazonensis 50 L. chagasi 50 ND CC 50 31  Da Silva et al. (2007) 11b  L. amazonensis 50 L. amazonensis 50 L. chagasi 50 ND CC 50 30  Da Silva et al. (2007) 11c  L. amazonensis 50 L. amazonensis 50 L. chagasi 50 ND CC 50 24  Da Silva et al. (2007) 12a  L. (V) panamensis 50 ND CC 50 0.89  Coa et al. (2017) 12b  L. (V) panamensis 50 ND CC 50 0.56  Coa et al. (2017) 12c  L. (V) panamensis 50 ND CC 50 4.9  Coa et al. (2017) 12d  L. (V) panamensis 50 ND CC 50 5.6  Coa et al. (2017) Polisubstitution 13  L. donovani 50 84% inhibition of parasite growth (hydrochloride salt) CC 50 187  Gopinath et al. (2013) 14  L. donovani 50 ND CC 50 122  Loiseau et al. (2011) 15  L. donovani 50 L. donovani 50 >80% reduction of parasite burden in liver and spleen CC 50 57.9  Upadhyay et al. (2019) 16  L. mexicana 50 L. donovani BPK282 50 L. donovani BPK275 50 L. donovani BPK173 50 Showed toxicity CC 50 31  Hammill et al. (2021) 17  L. mexicana 50 No activity CC 50 17  Hammill et al. (2021) 18a  L. donovani 50 L. donovani 50 40.36% CC 50 5.6  Upadhyay et al. (2018) 19a  L. donovani 50 L. donovani 50 17.29% CC 50 7.1  Upadhyay et al. (2018) 20  L. infantum 50 L. infantum 50 L. amazonensis 50 L. amazonensis 50 ND IC 50 177.1  Tavares et al. (2018) 21  L. mexicana 50 ND ND -  Isaac-Marquez et al. (2010) Note: promastigote (P), amastigote (A), ND, not determined. In summary, in the last decades, the development of new quinoline-derived compounds as potential chemotherapeutic agents for the treatment of leishmaniasis has increased. This remains a significant challenge due to multiple causes, such as the numerous species that cause the disease, diverse manifestations, resistance, and more. The quinoline framework interacts with different receptors, ion channels, and enzymes, making it a privileged scaffold in organic chemistry for the search for bioactive compounds; many natural and synthetic derivatives have been shown to exhibit a wide range of biological properties. In this mini-review, we presented an overview of the impact of substitution position on the antileishmanial properties of substituted quinolines. Considering all examples mentioned, it can be observed that, among monosubstituted quinolines, 2-substitution results in compounds with greater in vitro in vivo in vitro Leishmania 50 in vivo Leishmania Acknowledgements The authors thank UBA (UBACYT 20020190100242BA) and CONICET (PIP 11220210100072) for partial financial support.  Edited by: Gustavo Benaim  Reviewed by: Jaime Charris  Elena Aguilera Author contributions OE: Formal Analysis, Writing – original draft, Visualization, Conceptualization, Investigation, Writing – review and editing. GG: Investigation, Formal Analysis, Writing – original draft, Writing – review and editing, Funding acquisition, Visualization, Project administration, Conceptualization. Conflict of interest Authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Generative AI statement The author(s) declare that no Generative AI was used in the creation of this manuscript. Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us. Publisher’s note All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. References Aatif M. Raza M. A. Javed K. Nashre-ul-Islam S. M. Farhan M. Alam M. W. 2022 Potential nitrogen-based heterocyclic compounds for treating infectious diseases: a literature review Antibiotics 11 1750 10.3390/antibiotics11121750 36551407 PMC9774632 Afzal O. Kumar S. Haider M. R. Ali M. R. Kumar R. Jaggi M. 2015 A review on anticancer potential of bioactive heterocycle quinoline Eur. J. Med. Chem. 97 871 910 10.1016/j.ejmech.2014.07.044 25073919 Ajani O. O. Iyaye K. T. Ademosun O. T. 2022 Recent advances in chemistry and therapeutic potential of functionalized quinoline motifs–a review RSC Adv. 12 18594 18614 10.1039/d2ra02896d 35873320 PMC9231466 Almandil N. B. Taha M. Rahim F. Wadood A. Imran S. Alqahtani M. A. 2019 Synthesis of novel quinoline-based thiadiazole, evaluation of their antileishmanial potential and molecular docking studies Bioorg. Chem. 85 109 116 10.1016/j.bioorg.2018.12.025 30605884 Alodeani E. A. Arshad M. Izhari M. A. 2015 Antileishmanial activity and computational studies of some hydrazone derivatives possessing quinoline nucleus Eur. J. Pharm. Med. Res. 2 324 328 Ammar Y. A. Abd El-Hafez S. M. Hessein S. A. Ali A. M. Askar A. A. Ragab A. 2021 One-pot strategy for thiazole tethered 7-ethoxy quinoline hybrids: synthesis and potential antimicrobial agents as dihydrofolate reductase (DHFR) inhibitors with molecular docking study J. Mol. Struct. 1242 130748 10.1016/j.molstruc.2021.130748 Avanzo R. E. García Liñares G. Rodríguez N. Romero A. H. 2025 A comprehensive revision on the use of quinoline antimalarial drugs as leishmanicidal agents Front. Chem. 13 1608340 10.3389/fchem.2025.1608340 40520678 PMC12163007 Bhat S. Y. Bhandari S. Thacker P. S. Arifuddin M. Qureshi I. A. 2021 Development of quinoline‐based hybrid as inhibitor of methionine aminopeptidase 1 from Leishmania donovani Chem. Biol. Drug Des. 97 315 324 10.1111/cbdd.13783 32816410 Brindha J. Balamurali M. M. Chanda K. 2021 An overview on the therapeutics of neglected infectious diseases—leishmaniasis and Chagas diseases Front. Chem. 9 622286 10.3389/fchem.2021.622286 33777895 PMC7994601 Chanquia S. N. Larregui F. Puente V. Labriola C. Lombardo E. García Liñares G. 2019 Synthesis and biological evaluation of new quinoline derivatives as antileishmanial and antitrypanosomal agents Bioorg. Chem. 83 526 534 10.1016/j.bioorg.2018.10.053 30469145 Coa J. C. Castrillón W. Cardona W. Carda M. Ospina V. Muñoz J. A. 2015 Synthesis, leishmanicidal, trypanocidal and cytotoxic activity of quinoline-hydrazone hybrids Eur. J. Med. Chem. 101 746 753 10.1016/j.ejmech.2015.07.018 26218652 Coa J. C. García E. Carda M. Agut R. Vélez I. D. Muñoz J. A. 2017 Synthesis, antileishmanial, trypanocidal and cytotoxic activities of quinoline-chalcone and quinoline-chromone hybrids Med. Chem. Res. 26 1405 1414 10.1007/s00044-017-1846-5 Coa J. C. Yepes A. Carda M. Conesa‐Milián L. Upegui Y. Robledo S. M. 2020 Synthesis, in silico ChemSelect 5 2918 2924 10.1002/slct.201903835 da Silva L. E. Joussef A. C. Pacheco L. K. da Silva D. G. Steindel M. Rebelo R. A. 2007 Synthesis and in vitro N Bioorg. Med. Chem. 15 7553 7560 10.1016/j.bmc.2007.09.007 17889546 Delgado F. Benítez A. Gotopo L. Romero A. 2025 4-Aminoquinoline: a comprehensive review of synthetic strategies Front. Chem. 13 1553975 10.3389/fchem.2025.1553975 40291373 PMC12023255 Fakhfakh M. A. Fournet A. Prina E. Mouscadet J. F. Franck X. Hocquemiller R. 2003 Synthesis and biological evaluation of substituted quinolines: potential treatment of protozoal and retroviral co-infections Bioorg. Med. Chem. 11 5013 5023 10.1016/j.bmc.2003.09.007 14604664 Fournet A. Barrios A. A. Muñoz V. Hocquemiller R. Cavé A. Bruneton J. 1993 2-substituted quinoline alkaloids as potential antileishmanial drugs Antimicrob. Agents Chemother. 37 859 863 10.1128/aac.37.4.859 8494383 PMC187784 Fournet A. Ferreira M. E. Rojas De Arias A. Torres De Ortiz S. Fuentes S. Nakayama H. 1996  In vivo Leishmania amazonensis Antimicrob. Agents Chemother. 40 2447 2451 10.1128/aac.40.11.2447 8913444 PMC163555 Franck X. Fournet A. Prina E. Mahieux R. Hocquemiller R. Figadère B. 2004 Biological evaluation of substituted quinolines Bioorg. Med. Chem. Lett. 14 3635 3638 10.1016/j.bmcl.2004.05.026 15203133 García E. Coa J. C. Otero E. Carda M. Vélez I. D. Robledo S. M. 2018 Synthesis and antiprotozoal activity of furanchalcone–quinoline, furanchalcone–chromone and furanchalcone–imidazole hybrids Med. Chem. Res. 27 497 511 10.1007/s00044-017-2076-6 García Liñares G. Ravaschino E. L. Rodriguez J. B. 2006 Progresses in the field of drug design to combat tropical Protozoan parasitic diseases Curr. Med. Chem. 13 335 360 10.2174/092986706775476043 16475941 Gopinath V. S. Pinjari J. Dere R. T. Verma A. Vishwakarma P. Shivahare R. 2013 Design, synthesis and biological evaluation of 2-substituted quinolines as potential antileishmanial agents Eur. J. Med. Chem. 69 527 536 10.1016/j.ejmech.2013.08.028 24095747 Hammill J. T. Sviripa V. M. Kril L. M. Ortiz D. Fargo C. M. Kim H. S. 2021 Amino-substituted 3-aryl-and 3-heteroarylquinolines as potential antileishmanial agents J. Med. Chem. 64 12152 12162 10.1021/acs.jmedchem.1c00813 34355566 PMC8404201 Heravi M. M. Zadsirjan V. 2020 Prescribed drugs containing nitrogen heterocycles: an overview RSC Adv. 10 44247 44311 10.1039/D0RA09198G 35557843 PMC9092475 Hu Y. Q. Gao C. Zhang S. Xu L. Xu Z. Feng L. S. 2017 Quinoline hybrids and their antiplasmodial and antimalarial activities Eur. J. Med. Chem. 139 22 47 10.1016/j.ejmech.2017.07.061 28800458 Isaac-Márquez A. P. McChesney J. D. Nanayakara N. D. Satoskar A. R. Lezama-Dávila C. M. 2010 Antileishmanial activity of racemic±8-[(4-Amino-1-methylbutyl) amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline Nat. Prod. Comm. 5 387 390 10.1177/1934578X1000500309 20420313 Katsuno K. Burrows J. N. Duncan K. van Huijsduijnen R. H. Kaneko T. Kita K. 2015 Hit and lead criteria in drug discovery for infectious diseases of the developing world Nat. Rev. Drug Discov. 14 751 758 10.1038/nrd4683 26435527 Kumari D. Perveen S. Sharma R. Singh K. 2021 Advancement in leishmaniasis diagnosis and therapeutics: an update Eur. J. Pharmacol. 910 174436 10.1016/j.ejphar.2021.174436 34428435 Loiseau P. M. Gupta S. Verma A. Srivastava S. Puri S. K. Sliman F. 2011  In vitro Leishmania donovani Antimicrob. Agents Chemother. 55 1777 1780 10.1128/AAC.01299-10 21220526 PMC3067194 Mao W. Daligaux P. Lazar N. Ha-Duong T. Cavé C. van Tilbeurgh H. 2017 Biochemical analysis of leishmanial and human GDP-Mannose Pyrophosphorylases and selection of inhibitors as new leads Sci. Rep. 7 751 10.1038/s41598-017-00848-8 28389670 PMC5429698 Marshall C. M. Federice J. G. Bell C. N. Cox P. B. Njardarson J. T. 2024 An update on the nitrogen heterocycle compositions and properties of US FDA-approved pharmaceuticals (2013–2023) J. Med. Chem. 67 11622 11655 10.1021/acs.jmedchem.4c01122 38995264 Nakayama H. Loiseau P. M. Bories C. Torres de Ortiz S. Schinini A. Rojas de Arias A. 2005 Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniases Antimicrob. Agents Chemother. 49 4950 4956 10.1128/aac.49.12.4950-4956.2005 16304157 PMC1315925 Nakayama H. Desrivot J. Bories C. Franck X. Figadère B. Hocquemiller R. 2007  In vitro in vivo Leishmania donovani Biomed. Pharmacother. 61 186 188 10.1016/j.biopha.2007.02.001 17360145 Nefertiti A. S. G. Batista M. M. Da Silva P. B. Batista D. G. J. Da Silva C. F. Peres R. B. 2018  In vitro in vivo Antimicrob. Agents Chemother. 62 e01936-17 10.1128/aac.01936-17 29203485 PMC5786769 Ortiz D. Guiguemde W. A. Hammill J. T. Carrillo A. K. Chen Y. Connelly M. 2017 Discovery of novel, orally bioavailable, antileishmanial compounds using phenotypic screening PLoS Neglected Trop. Dis. 11 e0006157 10.1371/journal.pntd.0006157 29287089 PMC5764437 Pradhan S. Schwartz R. A. Patil A. Grabbe S. Goldust M. 2022 Treatment options for leishmaniasis Clin. Experim. Dermat. 47 516 521 10.1111/ced.14919 34480806 Rajesh Y. B. 2018 Quinoline heterocycles: synthesis and bioactivity Heterocycles-synthesis and biological activities Nandeshwarappa B. P. Sadashiv S. O. IntechOpen 10.5772/intechopen.81239 Ravindar L. Hasbullah S. A. Rakesh K. P. Hassan N. I. 2023 Recent developments in antimalarial activities of 4-aminoquinoline derivatives Eur. J. Med. Chem. 256 115458 10.1016/j.ejmech.2023.115458 37163950 Romero A. Delgado F. 2025 4-Aminoquinoline as a privileged scaffold for the design of leishmanicidal agents: structure–property relationships and key biological targets Front. Chem. 12 1527946 10.3389/fchem.2024.1527946 39981131 PMC11841433 Silva E. J. Bezerra-Souza A. Passero L. F. Laurenti M. D. Ferreira G. M. Fujii D. G. 2018 Synthesis, leishmanicidal activity, structural descriptors and structure–activity relationship of quinoline derivatives Future Med. Chem. 10 2069 2085 10.4155/fmc-2018-0124 30066582 Silva Santos S. de Araujo R. V. Giarolla J. El Seoud O. Ferreira E. I. 2020 Searching for drugs for Chagas disease, leishmaniasis and schistosomiasis: a review Int. J. Antimicrob. Agents 55 105906 10.1016/j.ijantimicag.2020.105906 31987883 Singh A. Kaur H. Arora S. Bedi P. M. S. 2022 Design, synthesis, and biological evaluation of novel morpholinated isatin–quinoline hybrids as potent anti‐breast cancer agents Arch. Pharm. 355 2100368 10.1002/ardp.202100368 34783073 Taha M. Ismail N. H. Ali M. Rashid U. Imran S. Uddin N. 2017 Molecular hybridization conceded exceptionally potent quinolinyl-oxadiazole hybrids through phenyl linked thiosemicarbazide antileishmanial scaffolds: in silico Bioorg. Chem. 71 192 200 10.1016/j.bioorg.2017.02.005 28228228 Tavares G. D. S. V. Mendonça D. V. C. Lage D. P. Granato J. D. T. Ottoni F. M. Ludolf F. 2018 Antileishmanial activity, cytotoxicity and mechanism of action of clioquinol against Leishmania infantum Leishmania amazonensis Basic Clin. Pharmacol. Toxic. 123 236 246 10.1111/bcpt.12990 29481714 Teng P. Li C. Peng Z. Marie V. A. Nimmagadda A. Su M. 2018 Facilely accessible quinoline derivatives as potent antibacterial agents Bioorg. Med. Chem. 26 3573 3579 10.1016/j.bmc.2018.05.031 29858158 PMC6084461 Upadhyay A. Kushwaha P. Gupta S. Dodda R. P. Ramalingam K. Kant R. 2018 Synthesis and evaluation of novel triazolyl quinoline derivatives as potential antileishmanial agents Eur. J. Med. Chem. 154 172 181 10.1016/j.ejmech.2018.05.014 29793211 Upadhyay A. Chandrakar P. Gupta S. Parmar N. Singh S. K. Rashid M. 2019 Synthesis, biological evaluation, structure–activity relationship, and mechanism of action studies of quinoline–metronidazole derivatives against experimental visceral leishmaniasis J. Med. Chem. 62 5655 5671 10.1021/acs.jmedchem.9b00628 31124675 Vandekerckhove S. Tran H. G. Desmet T. D’hooghe M. 2013 Evaluation of (4-aminobutyloxy) quinolines as a novel class of antifungal agents Bioorg. Med. Chem. Lett. 23 4641 4643 10.1016/j.bmcl.2013.06.014 23838261 Viegas-Junior C. Danuello A. da Silva Bolzani V. Barreiro E. J. Fraga C. A. M. 2007 Molecular hybridization: a useful tool in the design of new drug prototypes Curr. Med. Chem. 14 1829 1852 10.2174/092986707781058805 17627520 World Health Organization 2025 Leishmaniasis Available online at: https://www.who.int/es/news-room/fact-sheets/detail/leishmaniasis Yaluff G. Herrera L. Rolón M. S. Vega C. Cerecetto H. 2025 The quinoline framework and related scaffolds in natural products with anti-Leishmania properties Front. Chem. 13 1571067 10.3389/fchem.2025.1571067 40351526 PMC12061677 ",
  "metadata": {
    "Title of this paper": "The quinoline framework and related scaffolds in natural products with anti-Leishmania properties",
    "Journal it was published in:": "Frontiers in Chemistry",
    "URL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12476949/"
  }
}